New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
07:07 EDTBLUEbluebird bio recommended ahead of trial updates at JPMorgan
JPMorgan recommends owning shares of bluebird bio ahead of upcoming clinical trial updates. The firm notes initial data from the Phase 1/2 HGB-205 study evaluating LentiGlobin in beta-thalassemia patients will be presented on June 14 at the European Hematology Association. JPMorgan has an Overweight rating on the stock with a $44 price target.
News For BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2015
08:34 EDTBLUEJPMorgan views bluebird bio selloff as 'highly compelling opportunity'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use